A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Recruiting

Phase 1

PF-08049820 with Midazolam, Dabigatran, Birth ControlA Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Sponsor:

Pfizer

Code:

NCT07190430

Conditions

Atopic Dermatitis

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Interventions

PF-08049820

Midazolam

Dabigatran Etexilate

Portia (EE and LN) or equivalent oral tablet

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-22. This information was provided to ClinicalTrials.gov by Pfizer on 2025-10-21.